O le nasal cannula ose masini fa'afoma'i e tu'uina atu le okesene i le isu. O lona mamanu e fai si faigofie ona fa'amama ma e umi lona ola pe a tausia lelei. Nasal cannulas e faʻaaogaina e tuʻuina atu ai le okesene pe a manaʻomia se tafe maualalo, maualalo poʻo le feololo, ma o loʻo i ai le tagata maʻi i se tulaga mautu. Nasal cannulas e faʻaaogaina le okesene maualuga ma se faʻamama e tuʻuina atu i le tagata maʻi le okesene.

O le tafe maualuga o cannulas e pa'u i nisi o tetee mai le tafe mai le manava, ma mafua ai le faateleina o le mamafa o le ea. O lenei fa'atuputeleina o le mamafa o le ea o lo'o fa'aalia i le fa'ata'ita'iga pepe fou e aunoa ma se alatoto fa'atapula'a le mamafa. Ina ia aloese mai faʻamaʻi, e tatau i tagata gasegase ona faʻamama maeʻaeʻa le paipa cannula aʻo leʻi faʻaaogaina. Ina ia mautinoa o le cannula e leai se siama ma leai ni siama, e tatau ona faʻamamaina i le vineta paʻepaʻe ma le vai mafanafana. O le vineka e tape ai siama ae e le 'aina ai mea fa'aapa paipa. Ona tatau lea ona fufulu le cannula i le vai malulu e aveese ai le fasimoli ma siama. Ona tatau lea ona faʻamago le cannula aʻo leʻi faʻaaogaina. O le suia o cannulas e taua tele mo tagata mamaʻi o loʻo mafatia i le manava.

Taavale Taʻavale:

O le maualuga o le faʻamaʻi o le sela e faʻamoemoe e faʻateleina le tuputupu aʻe o le maketi o le nasal cannula i le lalolagi i luga o le vaitau o faʻataʻitaʻiga. Mo se faʻataʻitaʻiga, e tusa ai ma le Global Asthma Report 2018, o le faʻateleina o faʻamaʻi fomaʻi e 23% ma le faʻateleina o suʻesuʻega faʻafomaʻi o le sela 12% i Pasila.

Avanoa Maketi:

O le faʻateleina o gaosiga gafatia e faʻamoemoe e ofoina atu avanoa faʻatupulaia manuia mo tagata taʻalo i le maketi o le nasal cannula i le lalolagi. Mo se faʻataʻitaʻiga, ia Iuni 2020, Vapotherm, Inc. na faʻalauteleina ana mea faʻapitoa gaosiga gafatia e mafai ai e le kamupani ona faʻateleina le gaosiga o ana Faʻatonu Faʻatonu faiga e oʻo atu i le 20X i luga aʻe o le COVID-19 tulaga faʻamaʻi.

Fefaʻatauaiga Tala:

Amerika Latina e faʻamoemoe e molimauina le tele o le tuputupu aʻe i le maketi o le nasal cannula i le lalolagi, ona o le maualuga o faʻamaʻi faʻamaʻi faʻamaʻi. Mo se faʻataʻitaʻiga, e tusa ai ma Globocan 2018, Brazil na faʻamauina 559, 371 mataupu fou o le kanesa o le mama i le 2018. E tusa ai ma le suʻesuʻega 'Chronic Obstructive Pulmonary Disease in Latin America', lomia ia Ianuari 2019 i le tusi talaaga Annals of Global Health, o le taatele o COPD i aai Latina Amerika sa i le va o le 6.2 ma le 19.6% i tagata taʻitoʻatasi e 40 tausaga ma luga atu.

O le tulaʻi mai o le Covid-19 ua mafua ai ona faʻateleina le faʻaaogaina o le nasal cannula. I le lalolagi atoa, e oʻo i le 5:14pm CET, 17 Tesema 2021, e 271,963,258 faʻamaonia mataupu o le COVID-19, e aofia ai le 5,331,019 maliu, lipotia i le WHO. E oʻo mai i le aso 16 Tesema 2021, e 8,337,664,456 tui puipui na faia.

Laufanua tauvaga:

O tagata taʻalo tetele o loʻo galulue i le maketi o le nasal cannula i le lalolagi e aofia ai, Allied Healthcare Products, Besmed Health Business Corp., Drive Devilbiss International, Edward LifeSciences Corp., Fairmont Medical, Flexicare Medical, Medtronic plc., Maquet Holding BV & Co. KG , Medin Medical Innovations, Salter Labs, Sorin Group, Smiths Medical, Terumo Corporation, Teleflex Incorporated, Vapotherm Inc., ma Well Lead Medical Co. Ltd.

OA MEA E AVEA MAI LENEI TUSI:

Nasal cannulas are used to deliver oxygen when a low flow, low or medium concentration is required, and the patient is in a stable state.
For instance, according to The Global Asthma Report 2018, the prevalence of asthma symptoms was 23% and the prevalence of a medical diagnosis of asthma 12% in Brazil.
According to the study ‘Chronic Obstructive Pulmonary Disease in Latin America’, published in January 2019 in the journal Annals of Global Health, the prevalence of COPD in Latin American cities ranged between 6.